Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 10.396 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; purified talc; macrogol 6000; lactose; colloidal anhydrous silica; maize starch; mannitol; hypromellose; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: rosuzet composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe. homozygous familial hypercholesterolaemia (hofh): rosuzet composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: hypromellose; sodium stearylfumarate; macrogol 6000; mannitol; maize starch; lactose; microcrystalline cellulose; purified talc; colloidal anhydrous silica; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: ezalo composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh): ezalo composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - rosuvastatin calcium, quantity: 20.791 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; lactose; mannitol; purified talc; sodium stearylfumarate; macrogol 6000; microcrystalline cellulose; hypromellose; silicon dioxide; titanium dioxide; iron oxide yellow; iron oxide red - primary hypercholesterolaemia: rosuzet composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with rosuvastatin or ezetimibe alone; or - already treated with rosuvastatin and ezetimibe. homozygous familial hypercholesterolaemia (hofh): rosuzet composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).